Literature DB >> 12540791

Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study.

Isabelle O Colle1, Richard Moreau, Erica Godinho, Jacques Belghiti, Florence Ettori, Alain Cohen-Solal, Hervé Mal, Jacques Bernuau, Jean Marty, Didier Lebrec, Dominique Valla, François Durand.   

Abstract

Portopulmonary hypertension represents a major risk factor for transplantation; therefore, preoperative detection is crucial. The aims of this study were to determine (1) whether Doppler echocardiography performed at evaluation is a reliable tool for detecting portopulmonary hypertension and (2) the incidence of acquired portopulmonary hypertension profile after evaluation. One hundred sixty-five patients had Doppler echocardiography and right heart catheterization at evaluation over a 9-year period. All patients had a prospective follow-up, and the results of catheterization at evaluation were compared with those obtained at the time of transplantation. Seventeen of 165 patients met the criteria for portopulmonary hypertension on Doppler echocardiography. Portopulmonary hypertension was confirmed by catheterization in 10 patients and ruled out in 7. There were no false negatives for echocardiography. Mean pulmonary artery pressure was significantly higher during the initial phase of transplantation than at evaluation (17.8 +/- 4.3 vs. 20.3 +/- 5.5 mm Hg, respectively, P <.0001), and there was no significant correlation between values obtained at these 2 time points. Three patients showed to have acquired portopulmonary hypertension profile while waiting for a graft within time intervals ranging from 2.5 to 5 months. In conclusion, Doppler echocardiography is a highly sensitive tool for detecting portopulmonary hypertension. However, because this technique has a poor positive predictive value, right heart catheterization is recommended for confirming portopulmonary hypertension. In addition, the absence of portopulmonary hypertension at evaluation does not exclude the occasional occurrence of acquired portopulmonary hypertension profile after listing.

Entities:  

Mesh:

Year:  2003        PMID: 12540791     DOI: 10.1053/jhep.2003.50060

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  53 in total

Review 1.  [Extracardiac causes of right ventricular insufficiency].

Authors:  B Maisch; M Christ
Journal:  Internist (Berl)       Date:  2004-10       Impact factor: 0.743

2.  Pulmonary complications of cirrhosis.

Authors:  Rajan Kochar; Moises I Nevah Rubin; Michael B Fallon
Journal:  Curr Gastroenterol Rep       Date:  2011-02

3.  Portopulmonary hypertension in pediatric patients.

Authors:  Adria A Condino; D Dunbar Ivy; Judith A O'Connor; Michael R Narkewicz; Sarah Mengshol; John R Whitworth; Lori Claussen; Aimee Doran; Ronald J Sokol
Journal:  J Pediatr       Date:  2005-07       Impact factor: 4.406

Review 4.  Portopulmonary hypertension.

Authors:  Michael Halank; Ralf Ewert; Hans-Juergen Seyfarth; Gert Hoeffken
Journal:  J Gastroenterol       Date:  2006-09       Impact factor: 7.527

Review 5.  Epidemiology of pulmonary arterial hypertension.

Authors:  Xin Jiang; Zhi-Cheng Jing
Journal:  Curr Hypertens Rep       Date:  2013-12       Impact factor: 5.369

6.  Hemodynamic effects of ambrisentan-tadalafil combination therapy on progressive portopulmonary hypertension.

Authors:  Yu Yamashita; Ichizo Tsujino; Takahiro Sato; Asuka Yamada; Taku Watanabe; Hiroshi Ohira; Masaharu Nishimura
Journal:  World J Hepatol       Date:  2014-11-27

Review 7.  Sex, Gender, and Sex Hormones in Pulmonary Hypertension and Right Ventricular Failure.

Authors:  James Hester; Corey Ventetuolo; Tim Lahm
Journal:  Compr Physiol       Date:  2019-12-18       Impact factor: 9.090

8.  Serotonin transporter polymorphisms in patients with portopulmonary hypertension.

Authors:  Kari E Roberts; Michael B Fallon; Michael J Krowka; Raymond L Benza; James A Knowles; David B Badesch; Robert S Brown; Darren B Taichman; James Trotter; Steven Zacks; Evelyn M Horn; Steven M Kawut
Journal:  Chest       Date:  2009-01-13       Impact factor: 9.410

9.  Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease.

Authors:  Kari E Roberts; Michael B Fallon; Michael J Krowka; Robert S Brown; James F Trotter; Inga Peter; Hocine Tighiouart; James A Knowles; Daniel Rabinowitz; Raymond L Benza; David B Badesch; Darren B Taichman; Evelyn M Horn; Steven Zacks; Neil Kaplowitz; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2009-02-12       Impact factor: 21.405

Review 10.  Pulmonary vascular complications of liver disease.

Authors:  Jason S Fritz; Michael B Fallon; Steven M Kawut
Journal:  Am J Respir Crit Care Med       Date:  2012-11-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.